|
Release Date
15 February 2011
|
Expiration Date
15 February 2012
|
|
|
Sponsorship Statement
This activity is sponsored by prIME Oncology. |
Accreditation Statement
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. |
Credit Designation Statement
prIME Oncology designates this enduring Internet-based activity for maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. |
Faculty
Marc Chamberlain, MD
Seattle Cancer Care Alliance
Seattle, Washington, United States
Michael Weller, MD
University Hospital of Zurich
Zurich, Switzerland
|
Target Audience
This educational activity is designed for medical oncologists and other healthcare providers involved and/or interested in the utility of antiangiogenic therapy in the management of glioblastoma. |
Overview
This module is fifth in a six part series in which international oncology experts engage in discussion and review updated clinical information regarding the utility of antiangiogenic therapy in the management of solid tumors. Participants may view an expert discussion and are provided with downloadable reference slides. |
Educational Objectives
Upon completion of this educational activity, participants should be able to:
- Describe the current standard of care for patients with glioblastoma
- Compare and contrast the mechanism of action, efficacy, and tolerability of various antiangiogenic agents and regimens containing antiangiogenic agents
- Evaluate the appropriate clinical implementation of antiangiogenic agents based on available data
- Summarize the potential role of antiangiogenic agents for glioblastoma based on the clinical development programs
|
Method of Participation
There are no fees for participation in and receiving continuing medical education (CME) credits for this activity. In order to receive credit, participants must successfully complete the online post test and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you.
Links to the post tests are available on the activity selection page and video player pages.
|
Technical Requirements
To participate in this activity, your computer should have a processor the equivalent of Intel Pentium II 450 MHz or faster, with 128 MB of RAM and a connection to the Internet.
Estimated time to complete activity: 25 minutes
|
Support Statement
Support for this activity has been provided by an unrestricted educational grant from F. Hoffmann-La Roche, Ltd.
|
Disclosure of Conflicts of Interest
In accordance with the ACCME standards for Commercial Support, educational activities sponsored by prIME Oncology must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, and planning committee members participating in a prIME Oncology–sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
FACULTY
Dr Chamberlain has disclosed that he has received CME consulting fees from F. Hoffmann-La Roche Ltd; Merck & Co., Inc; Exelixis; and Sigma Tau Pharmaceuticals. Also he received fees for non-CME services from F. Hoffmann-La Roche Ltd; Merck & Co., Inc; Exelixis; and Sigma Tau Pharmaceuticals. None of these relationships will impact his ability to present an unbiased discussion.
Dr Weller has disclosed that he has received CME consulting fees from F. Hoffmann-La Roche Ltd, Merck Serono, and Merck Sharp & Dohme Limited. He has also performed contracted research for F. Hoffmann-La Roche Ltd, and Merck Serono. None of these relationships will impact his ability to present an unbiased discussion.
PLANNERS
Nathan Kelly, PhD (clinical) – no real or apparent conflicts of interest
Trudy Stoddert, ELS (editorial) – no real or apparent conflicts of interest
Susan H. Yarbrough, CCMEP (compliance) – no real or apparent conflicts of interest
|
Disclosure of Unlabeled Use
Participants have implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
|
